RXRX

Recursion Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 1/10
  • Value↓ 0/10
Recursion Pharmaceuticals sales and earnings growth
RXRX Growth
Low
  • Revenue Y/Y↑ 26.92%
  • EPS Y/Y↑ 14.79%
  • FCF Y/Y↓ -1.45%
Recursion Pharmaceuticals gross and profit margin trends
RXRX Profitability
Fair
  • Gross margin ↓ 5.00%
  • EPS margin↓ -863.40%
  • ROIC 5Y↓ -264.80%
Recursion Pharmaceuticals net debt vs free cash flow
RXRX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Recursion Pharmaceuticals stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗